[ad_1]
In 2021, I wrote a put up on microRNA (miRNA) and hair development. In there, I additionally discusses messenger RNA (mRNA). Now we have now RNA interference (RNAi) as a hair loss remedy. Thanks to OliX Pharmaceuticals (South Korea).
Update: November 22, 2022 — OliX just published preclinical analysis on its androgenetic alopecia remedy program, OLX104C. The outcomes are very encouraging. Actual study is here and the researchers demonstrated:
“Efficacy of androgen receptor (AR) reduction, hair loss inhibition, and long duration of action in primary cultured human follicle dermal papilla cells (HFDPC) and rodent models of hair loss.”
They name this know-how “cp-asiRNA targeting AR” and “AR-targeting asiRNA (cp-asiAR)”. The asiRNA stands for uneven small interfering RNA.
Update: May 27, 2022 — OliX simply raised $45 million and their androgenetic alopecia product (OLX104C) will enter scientific trials later this yr.
Update: August 2021 — OliX will get Notice of Allowance from US Patent and Trademark Office for OLX104C.
OliX Pharmaceuticals RNAi Hair Loss Product OLX104C
OliX Pharmaceuticals (South Korea) just made a major announcement. Their RNAi based mostly hair loss product OLX104C efficiently grew again hair in mice following only one single injection. The mice have been affected by androgenetic alopecia resulting from them being given extra dihydrotestosterone (DHT).
“We are advancing a novel and potentially durable approach to treating hair loss” — CEO Dong Ki Lee
In this preclinical examine, OLX104C was administered topically to a mouse mannequin through an injection. The earlier than and after photographs are superb. Interestingly, they examine the outcomes to the anti-androgen Flutamide.
More importantly, OliX is the actual deal. Their news page could be very spectacular with common important developments. This consists of elevating $37.2 million in December 2020 (h/t reader “James”). They additionally obtained US FDA Phase 2a approval in November, 2020 to deal with hypertrophic scars.
siRNA
On OliX’s pipeline web page, they state that small interfering RNA (siRNA) has limitations when it comes to stability, supply and toxicity. This isn’t an issue with RNAi therapeutics. Edit: Per the patent, they’re utilizing uneven siRNA to inhibit male sample hair loss gene expression.
Update: OliX signs agreement with LGC Biosearch Technologies to speed up manufacturing of uneven siRNA for the remedy of androgenic alopecia. Dr. Lee will current at right now’s SMi’s 12th Annual RNA Therapeutics virtual conference. He will focus on OLX104C at this occasion. OliX plans to provoke scientific trials of OLX104C “by 2022”.
Update: January 2022 — A brand new South Korean firm named siRNAgen Therapeutics (a subsidiary of Bioneer) is creating a SAMiRNA based hair loss product. SAMiRNA is a brand new kind of siRNA nanoparticle that doesn’t end in innate immune stimulation.
Update: March 2022 — Bioneer updates us on its new CosmeRNA product. Looks like they might launch it in South Korea and Germany (plus EU) this yr.
“Cosmerna is the world’s first short-interfering RNA (siRNA) gene technology-based functional cosmetic for alleviating hair loss symptoms”.
Hundreds of thousands and thousands of individuals world wide will take mRNA vaccines in the course of the subsequent a number of years. In impact, it will pace up scientific progress and trigger many to not fear about long-term unwanted side effects. Perhaps a mistake, however I’ll selfishly not complain an excessive amount of if it hurries up the belief of a hair loss remedy.
[ad_2]
Source by [author_name]